ArticleDrugs - real world outcomes2026
Three-Year Interim Results from a Post-Marketing Surveillance Study of Patients with Migraine Treated with Fremanezumab in South Korea.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is limited real-world evidence on the safety and effectiveness of fremanezumab in South Korea.
objectiveWe aimed to evaluate the safety and effectiveness of fremanezumab as a preventive migraine treatment in adults with migraine in real-life clinical practice in South Korea.
methodsA 6-year, non-interventional, prospective, post-marketing surveillance study conducted in up to 60 clinics and hospitals in South Korea from July 2021 to 2027. Eligible participants are aged ≥ 18 years, have a formal migraine diagnosis, and are receiving fremanezumab for the first time. The primary endpoint is the proportion of new adverse events, including serious adverse events, from first administration of fremanezumab to the 12-week observation period or discontinuation. Secondary endpoints include the mean change from baseline to week 12 in average monthly migraine days (MMD), proportion of participants achieving a ≥ 50% reduction in MMD, and the Patient Global Impression of Change (PGIC) scale at week 12. We present an interim analysis of data collected up to the third year of this study.
resultsAs part of the overall study, this 3-year interim analysis included data from 14 sites, with 1230 participants for safety and 1096 for effectiveness analyses (mean age: 46.1 years, standard deviation: 13.7; episodic/chronic migraine: 45.2%/54.8%; mean disease duration: 6.9 years [standard deviation 8.2]). Adverse events were reported by 17.6% of participants; the most common were injection-site reactions (5.7%); serious adverse events were infrequent (1.0%). After 12 weeks of treatment, mean change from baseline in MMD was - 7.8 ± 8.1 days (episodic migraine: - 3.4 ± 4.5 days, chronic migraine: - 11.4 ± 8.7 days), all p < 0.0001; 56.5% of participants (episodic migraine: 55.0%, chronic migraine: 57.7%) achieved a ≥ 50% reduction in MMD. Most participants (87.0%) rated treatment as effective on the PGIC scale.
conclusionsFremanezumab was well tolerated and effective for migraine prevention in Korean adults in a real-world setting. These results support the use of fremanezumab in routine clinical practice across South Korea.
Identifiers
42410233What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.